Any advancement on TOPICAL FINASTERIDE

paulie72785

Established Member
Reaction score
9
Waiting for it but couldn't find anything so resorted to the forum.....Any trials or release dates estimation.....If any other TOPICAL treatment is their EVEN EXPERIMENTAL pls share.....Have a good day
 

zzzzz

Senior Member
My Regimen
Reaction score
148
when finasteride is applied topically enough of it goes systemic to have the same effect as taking it orally so it's virtually useless

source:

Int J Clin Pharmacol Ther. 2014 Jul 30. [Epub ahead of print]
A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers.

Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R.
Abstract

Objective: Finasteride, a selective inhibitor of type 2 5-alpha reductase isoenzyme, inhibits the conversion of testosterone to dihydrotestosterone (DHT) and is indicated in the treatment of male androgenetic alopecia. The study objective was to evaluate a newly developed finasteride 0.25% topical solution in comparison to the marketed finasteride 1 mg tablet, with respect to finasteride pharmacokinetics and suppressive effects on plasma DHT. Methods: 24 healthy men with androgenetic alopecia were randomized in a single center, open-label, parallel-group, exploratory study, and received either multiple scalp applications of the topical solution b.i.d. or oral doses of the reference tablet o.d. for 7 days. Plasma finasteride, testosterone and DHT concentrations were determined. Results: After multiple doses, mean (± SD) finasteride Cmax and AUC00-t corresponded to 0.46 ± 0.28 ng/mL and 6.64 ± 7.50 ng/mL x h for the topical solution and to 6.86 ± 1.78 ng/mL and 57.93 ± 29.38 ng/mL x h for the tablet. Plasma DHT was reduced by ~ 68 - 75% with the topical solution and by ~ 62 - 72% with the tablet. No relevant changes occurred for plasma testosterone with either treatment. No clinically significant adverse events occurred. Conclusions: A strong and similar inhibition of plasma DHT was found after 1 week of treatment with the topical and tablet finasteride ormulations, albeit finasteride plasma exposure was significantly lower with the topical than with the oral product (p < 0.0001).
 
Top